About GI CanCER

Colorectal cancer is among the most prevalent cancers today, and its symptoms often mimic less severe conditions, which means it is frequently detected only at more advanced stages when treatment options are more limited and outcomes are poorer. Moreover, colorectal and other gastrointestinal cancers are especially prone to developing chemoresistance, making them even harder to treat.

What happens when cancer cells adapt to chemotherapy?
The AdResCanCER Action aims to address this challenge by serving as a platform that brings together, for the first time, researchers, young investigators, clinicians, and SMEs working in gastrointestinal cancers across basic and clinical oncology, molecular biology, drug discovery and development, and computer science. Such a platform serves as a shared knowledge hub for GI chemoresistance, supporting the exchange of ideas, data, and expertise across the field. It connects researchers, clinicians, and other stakeholders working on related questions, encourages collaboration, and supports a more coordinated approach to understanding treatment response and resistance in GI cancers.

By bringing together expertise from different institutions and disciplines, it makes existing knowledge more accessible and easier to build on. It also supports the identification of relevant biomarkers and therapeutic targets, strengthens training and knowledge exchange, particularly for early-career researchers, and helps link molecular research more closely with clinical questions and needs.